MedTrace Logo

Follow-up Study on Chronic Myeloid Leukemia Patients Achieving Treatment-free Remission

NCT05439889 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-05-17

No results posted yet for this study

Summary

In recent years, the goal of stopping drug therapy, also known as treatment-free remission (TFR), is emerging as one of the management goals of chronic myeloid leukemia (CML) therapy. Because there is no available data on Asian patients with CML undergoing tyrosine kinase inhibitor discontinuation (TKI), the investigators plan to recruit chronic phase CML patients with deep treatment response and good medical compliance in Taiwan to evaluate the feasibility, safety and clinical consequences of TKI discontinuation.

Conditions

  • Chronic Myeloid Leukemia, BCR/ABL-Positive

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-11
Primary Completion
2028-08-11
Completion
2032-08-11

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05439889 on ClinicalTrials.gov